SCHEMBL7323221

SCHEMBL7323221

CCCCCN(CC(=O)OCC)C(=O)[C@H](CC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
CTSK P43235 5/20 0.43
CCKBR P32239 1/20 0.40
CTSS P25774 1/20 0.39
CYP2D6 P10635 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8719939 0.92 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7396101 0.82 SYK (0.46) CTSKCCKBRCTSS
SCHEMBL7396130 0.82 SMN1; SMN2 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL8717261 0.81 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7331692 0.81 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7301321 0.81 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL6822145 0.81 CTSK (0.42) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7335645 0.79 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL8719598 0.79 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7390964 0.79 CNR2 (0.42) CTSKCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0559046-B1 N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors HOFFMANN LA ROCHE (CH) 2001-07-11 EP disclosed
EP-0559046-A1 N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1993-09-08 EP disclosed